Emmanuel Giménez García, M. Portero, Concepción Boqué, Asunción Echeveste, R. Paz, S. Castillo, R. Calzada, J. González, V. García-Gutiérrez
{"title":"分析尼洛替尼在西班牙新诊断的慢性髓系白血病一线治疗中商业化后的预算影响","authors":"Emmanuel Giménez García, M. Portero, Concepción Boqué, Asunción Echeveste, R. Paz, S. Castillo, R. Calzada, J. González, V. García-Gutiérrez","doi":"10.1007/S40277-013-0004-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":101511,"journal":{"name":"PharmacoEconomics Spanish Research Articles","volume":"59 4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Análisis del impacto presupuestario tras la comercialización de nilotinib en el tratamiento de primera línea en pacientes con leucemia mieloide crónica de nuevo diagnóstico en España\",\"authors\":\"Emmanuel Giménez García, M. Portero, Concepción Boqué, Asunción Echeveste, R. Paz, S. Castillo, R. Calzada, J. González, V. García-Gutiérrez\",\"doi\":\"10.1007/S40277-013-0004-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":101511,\"journal\":{\"name\":\"PharmacoEconomics Spanish Research Articles\",\"volume\":\"59 4 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Spanish Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/S40277-013-0004-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Spanish Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/S40277-013-0004-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Análisis del impacto presupuestario tras la comercialización de nilotinib en el tratamiento de primera línea en pacientes con leucemia mieloide crónica de nuevo diagnóstico en España